Investigational · not FDA approved

Editorially reviewed · Last updated May 2026 · How we review

ADA 2026 Retatrutide: TRANSCEND-T2D-1 & TRIUMPH-1 Panel (Jun 6-10)

ADA 2026: Retatrutide TRANSCEND-T2D-1 & TRIUMPH-1 Panel Preview

Event: ADA 86th Scientific Sessions · June 6-10, 2026 · New Orleans, LA · Ernest N. Morial Convention Center
The American Diabetes Association's 86th Scientific Sessions, held June 6-10, 2026 in New Orleans, will feature the most detailed public presentation to date of retatrutide's Phase 3 data. The TRANSCEND-T2D-1 and TRIUMPH-1 results — beyond what Lilly has shared in topline press releases — will be presented in a dedicated symposium on Saturday, June 6, from 1:30-3:00 p.m. in Great Hall A.

The Symposium

Title: Unlocking the Next Frontier in Treatment of Obesity and Type 2 Diabetes with Retatrutide: A Triple Agonist, Activating the GIP, GLP-1 and Glucagon Receptors (TRANSCEND-T2D-1 and TRIUMPH-1 Results)
Date: Saturday, June 6, 2026 Time: 1:30 – 3:00 p.m. (Central Time) Location: Great Hall A, Ernest N. Morial Convention Center, New Orleans On-demand access: Recorded presentations available to registered participants June 10 – August 10, 2026

Confirmed Speakers and Topics

SpeakerAffiliationTopic
Jonathan Campbell, PhDAssociate Professor of Medicine, Duke UniversityHow glucagon receptor agonism adds to the effect of GIP and GLP-1 receptor agonism
Kenneth Custer, PhDEVP & President, Lilly Cardiometabolic HealthTRANSCEND-T2D-1 detailed results
Additional Phase 3 investigators (TBA)TRANSCEND-T2D-1 and TRIUMPH-1 trialsFull topline data, subgroup analyses, safety
For the full ADA 2026 program, see ADA Meeting News.

What to Expect

1. Full TRANSCEND-T2D-1 results beyond the topline. Lilly's March 19 press release reported A1C reduction of 1.7-2.0% and 16.8% weight loss at 12 mg. The ADA session is expected to add:
  • Detailed subgroup analyses (by baseline A1C, diabetes duration, BMI)
  • Glycemic targets (% reaching A1C below 6.5% and 7.0%)
  • Detailed safety and tolerability data
  • Body composition changes (fat mass vs. lean mass)
  • Hypoglycemia rates (relevant given the glucagon receptor activation)
  • Cardiometabolic changes (lipids, blood pressure, hsCRP)
See our TRANSCEND-T2D-1 page for the topline summary.
2. TRIUMPH-1 first look. TRIUMPH-1 is the largest of the Phase 3 obesity registration trials and the most important for the eventual FDA filing. As of May 2026, full topline results have not been publicly released — ADA 2026 may be the venue for that disclosure. The TRIUMPH-1 portion of the session is expected to cover:
  • Mean weight loss at 9 mg and 12 mg doses
  • Comparison to historical Phase 3 trials of semaglutide and tirzepatide
  • Cardiometabolic and quality-of-life secondary endpoints
  • Safety, including the dysesthesia signal first observed in TRIUMPH-4
3. Triple-agonist mechanism deep dive. Dr. Campbell's talk on glucagon receptor agonism is expected to address how the third receptor distinguishes retatrutide from existing dual (tirzepatide) and single (semaglutide) agonists — particularly for hepatic metabolism, energy expenditure, and lean mass preservation. This is the mechanistic question that has driven the most analyst interest in retatrutide.

Why ADA 2026 Matters

Regulatory signal. Lilly has guided that retatrutide regulatory submissions will occur in 2026. The ADA 2026 session is one of the last major scientific venues before that filing, and the data presented here will shape physician expectations heading into the FDA review.
Insurance coverage trajectory. Payer formulary decisions begin with the scientific data presented at conferences like ADA and the resulting published peer-reviewed literature. Strong TRIUMPH-1 results presented here could accelerate coverage decisions ahead of approval.
Direct comparison with the rest of the obesity drug landscape. ADA 2026 also includes sessions on tirzepatide's long-term outcomes, oral GLP-1s (orforglipron), and survodutide. Retatrutide will be evaluated by the diabetes community against the full competitive set in real time.

How to Follow the Data

  • Live coverage of presentations will be available through ADA Meeting News and the major medical news outlets (CNBC, BioPharma Dive, Endpoints News, STAT News).
  • Full publications are typically released in New England Journal of Medicine, The Lancet, or Diabetes Care in coordination with major conference presentations.
  • Our News page will be updated throughout the week with each major readout from the session.

Frequently Asked Questions

When is the retatrutide ADA 2026 session?

Saturday, June 6, 2026, 1:30-3:00 p.m. Central Time, at Great Hall A of the Ernest N. Morial Convention Center in New Orleans, as part of the ADA 86th Scientific Sessions (June 6-10, 2026).

What new data will be revealed at ADA 2026?

Detailed TRANSCEND-T2D-1 results beyond the March 19 topline (subgroup analyses, full safety, body composition, glycemic targets) and the first detailed disclosure of TRIUMPH-1 (the largest Phase 3 obesity registration trial). Dr. Jonathan Campbell will also present on how glucagon receptor agonism adds to the GIP and GLP-1 mechanism.

Will TRIUMPH-1 results be announced at ADA 2026?

Likely yes. As of May 2026, TRIUMPH-1 topline results have not been publicly released. The ADA 2026 session title explicitly includes "TRIUMPH-1 Results," suggesting full topline data will be disclosed at the session.

How can I access the recorded presentations?

ADA registered attendees will have on-demand access to recorded presentations from June 10 through August 10, 2026, via the ADA Scientific Sessions virtual platform.

Sources

Medical disclaimer: This page is a preview of an upcoming scientific session and may include speculation about expected content. Retatrutide is not FDA approved. This is informational only, not medical advice. glp3.wiki is not affiliated with Eli Lilly, the ADA, or any pharmaceutical company.
How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Related reading

TRANSCEND-T2D-1: Retatrutide Phase 3 Diabetes Results (March 2026)
News

TRANSCEND-T2D-1: Retatrutide Phase 3 Diabetes Results (March 2026)

First Phase 3 retatrutide trial in type 2 diabetes — 16.8% weight loss and -2.0% A1C at 12 mg over 40 weeks. Announced March 19, 2026.

TRIUMPH-3 Retatrutide Results: 22.6% at 12 mg
News

TRIUMPH-3 Retatrutide Results: 22.6% at 12 mg

TRIUMPH-3 reported topline results on July 23, 2026 — 22.6% weight loss at 12 mg over 80 weeks in a cardiovascular-disease population.

Retatrutide for Knee Osteoarthritis: TRIUMPH-4
Explainer

Retatrutide for Knee Osteoarthritis: TRIUMPH-4

TRIUMPH-4, the first retatrutide Phase 3 readout (December 2025), showed 28.7% weight loss and 75.8% pain reduction in adults with obesity and knee osteoarthritis.

Retatrutide Phase 3 Results 2026: TRIUMPH Trial Tracker
Tracker

Retatrutide Phase 3 Results 2026: TRIUMPH Trial Tracker

Living tracker of every retatrutide trial — TRIUMPH-1/2/3/4/5, TRIUMPH-Outcomes, TRANSCEND-T2D-1/2, and SYNERGY-OUTCOMES Phase 3 readouts.

Retatrutide FDA Approval Timeline 2026-2028
Tracker

Retatrutide FDA Approval Timeline 2026-2028

Lilly plans a Q1 2027 BLA filing. TRIUMPH-1, -2 and -3 have reported. Approval window late 2027–28.